Universal Beteiligungs und Servicegesellschaft mbH Has $62.60 Million Stake in Qiagen N.V. (NYSE:QGEN)

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 26.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,580,260 shares of the company's stock after selling 568,021 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.71% of Qiagen worth $62,598,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QGEN. Envestnet Portfolio Solutions Inc. increased its position in Qiagen by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after purchasing an additional 341 shares during the last quarter. Pitcairn Co. increased its position in Qiagen by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after purchasing an additional 354 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Qiagen by 2.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares during the last quarter. Headlands Technologies LLC increased its position in Qiagen by 2.0% in the 4th quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock worth $883,000 after purchasing an additional 397 shares during the last quarter. Finally, LPL Financial LLC increased its position in Qiagen by 2.6% in the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after purchasing an additional 432 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Shares of QGEN traded up $0.57 during mid-day trading on Friday, reaching $51.80. The company had a trading volume of 1,215,792 shares, compared to its average volume of 1,474,402. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83. The company's 50-day moving average is $46.75 and its 200-day moving average is $43.21. The company has a market capitalization of $11.51 billion, a P/E ratio of 129.86, a P/E/G ratio of 2.63 and a beta of 0.68.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same period in the prior year, the firm posted $0.44 EPS. Qiagen's quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Dividend Announcement

The business also recently announced a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 0.52%. Qiagen's payout ratio is presently 62.50%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Redburn Atlantic lowered Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Robert W. Baird upped their price target on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Wall Street Zen downgraded Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Bank of America upped their price target on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Finally, Barclays initiated coverage on Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.